68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying tumors in patients with prostate cancer that has come back after a period of improvement (recurrent). 68Ga-PSMA is a radioactive drug that may attach to specific prostate cancer cells and light up. Scanners, such as PET/CT or PET/MRI, can then be used to take pictures of the body to see where the cancer is. Using 68Ga-PSMA for PET/CT or PET/MRI may allow doctors to identify smaller tumors than standard methods.

Study Type: Interventional

Endpoint Classification: Bio-availability Study

Intervention Model: Single Group Assignment

Masking: Open Label

Primary Purpose: Diagnostic

Official Title: 68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study

Estimated Enrollment: 10

Study Start Date: June 2015

Estimated Study Completion Date: June 2017

Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)

Arms:

Experimental: Diagnostic (68Ga-PSMA PET/CT or PET/MRI)

Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.